When a tetanus toxoid vaccination is indicated, pediatric patients treated with B-cell depleting therapy in the past 6 months should receive passive immunization, according to updated EULAR vaccine recommendations.
The recommendation on B-cell therapy is a new addition to the EULAR/PRES recommendations for the vaccination of pediatric patients with autoimmune inflammatory rheumatic diseases, which were first developed in 2011. The updated 2021 guidelines have been published in the Annals of the Rheumatic Diseases.
“Pediatric patients with AIIRD (pedAIIRD) are offered vaccines via National